Announcements Trials
Browse Landscape

Phase

Phase 2 4

Status

Recruiting 3Active not recruiting 1

Sponsor Class

OTHER 2NIH 2

Study Type

Interventional 4

Sponsor

Cancer Type

Head & Neck 4

Conditions

Carcinoma, Non-Small-Cell Lung 47Melanoma 23Neoplasm Metastasis 19Neoplasms 18Squamous Cell Carcinoma of Head and Neck 17Lung Neoplasms 13Skin Neoplasms 12Head and Neck Neoplasms 10Recurrence 9Carcinoma, Renal Cell 9Prostatic Neoplasms 8Ovarian Neoplasms 8Colorectal Neoplasms 8Carcinoma, Squamous Cell 8Breast Neoplasms 8Urinary Bladder Neoplasms 7Carcinoma, Merkel Cell 7Triple Negative Breast Neoplasms 6Colonic Neoplasms 6Carcinoma, Basal Cell 6Carcinoma 6Adenocarcinoma 6Uterine Cervical Neoplasms 5Pancreatic Neoplasms 5Stomach Neoplasms 4Sarcoma 4Multiple Myeloma 4Mouth Neoplasms 4Glioblastoma 4Fallopian Tube Neoplasms 4

Interventions

Cisplatin 30Magnetic Resonance Spectroscopy 21Radiotherapy 20pembrolizumab 18Specimen Handling 17Cetuximab 16Radiotherapy, Intensity-Modulated 11Paclitaxel 11Carboplatin 11Fluorouracil 10Biopsy 101,2-diaminocyclohexaneplatinum II citrate 10Radiation 9Platinum 9Drug Therapy 9Taxes 7Surgical Procedures, Operative 7Celecoxib 7X-Rays 6Standard of Care 6Sentinel Lymph Node Biopsy 6Surveys and Questionnaires 5Nivolumab 5cemiplimab 4Metformin 4Fluorodeoxyglucose F18 4Docetaxel 4Chemoradiotherapy 4(225)Ac-DOTA-c(RGDyK) 4durvalumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Mouth Neoplasms × cemiplimab × Clear all
NCT06448026 2026-05-20

Cemiplimab and Cetuximab Prior Salvage Surgery in Patients With Recurrent Oral Cavity Squamous Cell Carcinoma (OCSCC).

M.D. Anderson Cancer Center

Phase 2 Recruiting
17 enrolled
Head & Neck

Mouth Neoplasms

NCT07195734 2026-05-19

Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
180 enrolled
Head & Neck

Carcinoma, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT06980038 2026-05-13

Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
44 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Laryngeal Neoplasms, Mouth Neoplasms

NCT04862650 2026-02-10

Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Ohio State University Comprehensive Cancer Center

Phase 2 Active not recruiting
46 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡